Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3329-3334

  Masuda, Noriyuki ^a   Matsui, Kaoru ^a   Negoro, Shunichi ^a   Takifuji, Nobuhide ^a   Takeda, Kouji ^a   Yana, Takashi ^a   Kobayashi, Masashi ^a   Hirashima, Tomonori ^a   Kusunoki, Yoko ^a   Ushijima, Sunao ^a   Kawase, Ichiro ^a   Tada, Takuhito ^a   Sawaguchi, Hirochiyo ^a   Fukuoka, Masahiro ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ETOPOSIDE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031725727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3329     Document Type: Article

References (31)

1. Morstyn G, Ihde DC, Lichter AS, et al: Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515-539, 1984
2. Livingston RB, Stephens RL, Bonnet JD, et al: Long-term survival and toxicity in small cell lung cancer. Am J Med 77:415-417, 1984
3. Johnson BE, Ihde DC, Bunn PA, et al: Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 103:340-438, 1985
4. Fukuoka M, Masuda N, Matsui K, et al: Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up. Cancer 65:1678-1684, 1990
5. Ihde DC, Pass HI, Glatstein E: Small cell lung cancer, in DeVita VTJ, Hellman S, and Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott-Raven, 1997, pp 911-949
6. Albain KS, Crowley JJ, Hutchins L, et al: Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 72:1184-1191, 1993
7. Wang JC: DNA topoisomerases. Annu Rev Biochem 54:665-697, 1985
8. Masuda N, Kudoh S, Fukuoka M: Irinotecan (CPT-11): Pharmacology and clinical applications. Crit Rev Oncol Hematol 24:3-26, 1996
9. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
10. van Maanen JMS, Retel J, de Vries J, et al: Mechanism of action of antitumor drug etoposide: A review. J Natl Cancer Inst 80:1526-1533, 1988
11. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994
12. Sugiura T, Ota K, Fukuoka M, et al: A phase II study of recombinant human granulocyte colony stimulating factor in advanced lung cancer patients at risk for chemotherapy-induced neutropenia. Proc Am Assoc Cancer Res 30:408, 1989 (abstr)
13. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
14. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small cell lung cancer. J Clin Oncol 3:65-71, 1985
16. Lopez JA, Mann J, Grapski RT, et al: Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. Cancer Treat Rep 69:369-371, 1985
17. Porter LL, Johnson DH, Hainsworth JD, et al: Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 69:479-481, 1985
18. Masuda N, Fukuoka M, Matsui K, et al: Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 65:2635-2640, 1990
19. Aisner J: Extensive-disease small-cell lung cancer: The thrill of victory; The agony of defeat. J Clin Oncol 14:658-665, 1996
20. Kubota K, Nishiwaki Y, Kakinuma R, et al: Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15:292-296, 1997
21. Beck WT: Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases. J Natl Cancer Inst 81:1683-1685, 1989
22. Tan KB, Mattern MR, Eng W-K, et al: Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735, 1989
23. Sugimoto Y, Tsukahara S, Oh-hara T, et al: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962-7965, 1990
24. Bertrand R, O'Connor PM, Kerrigan D, et al: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992
25. Kim R, Hirabayashi N, Nishiyama M, et al: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992
26. D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924, 1990
27. Kaufmann SH: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991
28. Oshita F, Noda K, Nishiwaki Y, et al: Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304-309, 1997
29. Fukuoka M, Niitani H, Suzuki A, et al: Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992
30. Masuda N, Fukuoka M, Fujita A, et al: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small cell lung cancer. Br J Cancer 78:251-256, 1998
31. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994